arrow_back Back to App

Support for Medical Manufacturing in Economically Distressed Areas

This act aims to revitalize domestic medical manufacturing by offering tax incentives to companies that produce in economically distressed regions. This is intended to increase the availability of medicines and medical equipment, create new jobs in needy communities, and strengthen the nation's health security.
Key points
Companies manufacturing medical products in designated economically distressed zones can receive significant tax credits, reducing their operating costs.
Support also extends to the production of drugs and equipment critical for public health, including those protecting vulnerable populations during epidemics.
The act seeks to strengthen the domestic supply chain for medical products, reducing reliance on foreign suppliers and enhancing citizens' health security.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_447
Sponsor: Rescom. González-Colón, Jenniffer [R-PR-At Large]
Process start date: 2023-01-24
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

MMEDS Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_447.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-01-24.

What are the main provisions?

Key points include:

  • Companies manufacturing medical products in designated economically distressed zones can receive significant tax credits, reducing their operating costs.
  • Support also extends to the production of drugs and equipment critical for public health, including those protecting vulnerable populations during epidemics.
  • The act seeks to strengthen the domestic supply chain for medical products, reducing reliance on foreign suppliers and enhancing citizens' health security.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rescom. González-Colón, Jenniffer [R-PR-At Large].

What is the latest detailed status?

The latest detailed status is: Introduced in House

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health Taxes Economy